What is LOPJLB’s current signal on IMUX?

LOPJLB’s latest quantitative signal on Immunic, Inc. (IMUX) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is IMUX in?

Immunic, Inc. (IMUX) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Immunic, Inc. (IMUX) do?

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other…

Immunic, Inc. (IMUX)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$6.89-13.33%Close

SELLCRISIS · day 30

[SCORES & PROFILE]

FUND: 15
VALUE: 16
GROWTH: 47
GARP: 6
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-94.7%

REV YoY-

ROE-157.9%

EPS YoY-

ROA-70.1%

GROSS

NET

[VALUATION]

P/E TTM-1.44

P/E FWD-

SECTOR PE20.34

INDUSTRY PE13.84

P/B2.30

P/FCF-

EV/EBITDA0.54

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E0.44

ALTMAN Z-

CURR RATIO5.05

ND/EBITDA-

BETA1.45

FAQ

What is LOPJLB’s current signal on IMUX?: LOPJLB’s latest quantitative signal on Immunic, Inc. (IMUX) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is IMUX in?: Immunic, Inc. (IMUX) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Immunic, Inc. (IMUX) do?: Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other…

Immunic, Inc. (IMUX)

Key stats

Prediction markets

FUNDAMENTALS

Company news

FAQ